SUMMIT, N.J.--( / ) July 22, 2019 -- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behcet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behcet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat.
“Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behcet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who previously had limited options available.”
Behcet’s Disease, also known as Behcet’s Syndrome, affects approximately 5 in 100,000 people in the U.S.[1,2] Oral ulcers, the most common manifestation of Behcet’s Disease occurring in more than 98% of patients, can be painful, disabling and negatively affect quality of life.
“We are excited to provide the first and only FDA-approved treatment for oral ulcers associated with Behcet’s Disease,” said Terrie Curran, President, Celgene Inflammation & Immunology. “This approval is a reflection of Celgene’s commitment to research in areas of high unmet need, including rare diseases such as Behcet’s Disease. We remain dedicated to further studying OTEZLA and its role in inflammatory conditions.”
The FDA approval was based on efficacy and safety results from the randomized, placebo-controlled, double-blind Phase 3 RELIEF™ study evaluating OTEZLA in 207 adult patients with Behcet’s Disease with active oral ulcers who were previously treated with at least one nonbiologic medication and were candidates for systemic therapy. Results showed OTEZLA 30 mg BID resulted in a 42.7 point reduction from baseline in the pain of oral ulcers as measured by the visual analog scale (VAS) at week 12, compared with an 18.7 point reduction with placebo. The proportion of patients achieving an oral ulcer complete response (oral ulcer-free) at week 12 was 52.9% in the OTEZLA arm and 22.3% in the placebo arm. The proportion of patients achieving oral ulcer complete response by week 6 and who remained oral ulcer-free for at least six additional weeks during the 12-week treatment phase was 29.8% in the OTEZLA arm and 4.9% in the placebo arm. The daily average number of oral ulcers during the 12-week treatment phase was 1.5 in the OTEZLA arm and 2.6 in the placebo arm (based on oral ulcer counts measured at baseline and at weeks 1, 2, 4, 6, 8, 10 and 12).
“Behcet’s Disease is a chronic inflammatory disease in which patients present with symptoms such as oral ulcers that can have a significant impact on daily life,” said Mirta Avila Santos, M.D., Executive Director, American Behcet’s Disease Association. “Today’s approval for OTEZLA marks an important milestone for people with Behcet’s Disease who have been eagerly waiting for treatment options for their oral ulcers.”
The most common adverse events observed occurring in ≥10% of patients in the RELIEF trial were diarrhea (41.3% with OTEZLA; 20.4% for placebo), nausea (19.2% with OTEZLA; 10.7% for placebo), headache (14.4% with OTEZLA; 10.7% for placebo) and upper respiratory tract infection (11.5% with OTEZLA; 4.9% for placebo). The safety profile was consistent with the known safety profile of OTEZLA.
OTEZLA is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behcet’s Disease. Since its initial FDA approval in 2014, OTEZLA has been prescribed to more than 250,000 patients with moderate to severe plaque psoriasis or active psoriatic arthritis in the U.S.
OTEZLA is available in the U.S. and is dispensed through a comprehensive network of specialty pharmacies. For more information about accessing OTEZLA and patient support services (including reimbursement assistance and 24/7 nurse support), doctors and patients can contact OTEZLA® SupportPlus™ at 1-844-4OTEZLA (1-844-468-3952) or visit for more information.
Celgene anticipates a regulatory decision for OTEZLA in oral ulcers associated with Behcet’s Disease from the Pharmaceuticals and Medical Devices Agency in Japan in the second half of 2019. The Company also submitted a Type II Variation to the Marketing Authorization Application earlier this year seeking approval in the European Union.
About the RELIEF™ Study
The RELIEF™ study is a Phase 3 randomized, placebo-controlled, double-blind study evaluating OTEZLA 30 mg BID in 207 adult patients with Behcet’s Disease with active oral ulcers who were previously treated with at least one nonbiologic medication and were candidates for systemic therapy. This 64-week study was conducted at 53 sites across 10 countries.
In the study, 207 adult patients were randomized 1:1 to receive either OTEZLA 30 mg BID (n=104) or placebo (n=103) for the 12-week placebo-controlled treatment phase. Upon completion of week 12, all patients received OTEZLA for the 52-week active treatment phase. Efficacy was assessed based on the number and pain of oral ulcers, including the daily average number of oral ulcers during the 12-week placebo-controlled treatment phase.
About Behcet’s Disease
Behcet’s Disease is associated with abnormalities of the immune system and inflammation of the blood vessels. Behcet’s Disease is characterized by recurrent oral and genital ulcers, skin lesions, uveitis, arthritis, vascular, central nervous system and gastrointestinal involvement. Oral ulcers are present in more than 98% of Behcet’s Disease patients.
Behcet’s Disease has been classified in the U.S. as a rare or “orphan” disease by the National Institutes of Health. At this time, there are limited approved therapies to treat Behcet’s Disease in the U.S. Prevalence of Behcet’s Disease is highest in the Middle East, Asia and Japan.
About OTEZLA® (apremilast)
OTEZLA® (apremilast) 30 mg tablets is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators. The specific mechanism(s) by which OTEZLA exerts its therapeutic action in patients is not well defined.
U.S. PRESCRIBING INFORMATION
Otezla® (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behcet’s Disease.
IMPORTANT SAFETY INFORMATION
Otezla® (apremilast) is contraindicated in patients with a known hypersensitivity to apremilast or to any of the excipients in the formulation
Warnings and Precautions
Diarrhea, Nausea and Vomiting: Cases of severe diarrhea, nausea, and vomiting were associated with the use of Otezla. Most events occurred within the first few weeks of treatment. In some cases patients were hospitalized. Patients 65 years of age or older and patients taking medications that can lead to volume depletion or hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor patients who are more susceptible to complications of diarrhea or vomiting; advise patients to contact their healthcare provider. Consider Otezla dose reduction or suspension if patients develop severe diarrhea, nausea, or vomiting
Depression: Carefully weigh the risks and benefits of treatment with Otezla for patients with a history of depression and/or suicidal thoughts/behavior, or in patients who develop such symptoms while on Otezla. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes, and they should contact their healthcare provider if such changes occur
Psoriasis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.3% (12/920) of patients reported depression compared to 0.4% (2/506) on placebo. Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506). Suicidal behavior was observed in 0.1% (1/1308) of patients on Otezla, compared to 0.2% (1/506) on placebo. One patient treated with Otezla attempted suicide; one patient on placebo committed suicide
Psoriatic Arthritis: Treatment with Otezla is associated with an increase in depression. During clinical trials, 1.0% (10/998) reported depression or depressed mood compared to 0.8% (4/495) treated with placebo. Suicidal ideation and behavior was observed in 0.2% (3/1441) of patients on Otezla, compared to none in placebo-treated patients. Depression was reported as serious in 0.2% (3/1441) of patients exposed to Otezla, compared to none in placebo-treated patients (0/495). Two patients who received placebo committed suicide compared to none on Otezla.
Behcet’s Disease: Treatment with Otezla is associated with an increase in depression. During the clinical trial, 1% (1/104) reported depression or depressed mood compared to 1% (1/103) treated with placebo. No instances of suicidal ideation or behavior were reported in patients treated with Otezla or treated with placebo.
Weight Decrease: Monitor body weight regularly; evaluate unexplained or clinically significant weight loss, and consider discontinuation of Otezla
Psoriasis: Body weight loss of 5-10% occurred in 12% (96/784) of patients treated with Otezla and in 5% (19/382) of patients treated with placebo. Body weight loss of ≥10% occurred in 2% (16/784) of patients treated with Otezla compared to 1% (3/382) of patients treated with placebo
Psoriatic Arthritis: Body weight loss of 5-10% was reported in 10% (49/497) of patients taking Otezla and in 3.3% (16/495) of patients taking placebo.
Behcet’s Disease: Body weight loss of >5% was reported in 4.9% (5/103) of patients taking Otezla and in 3.9% (4/102) of patients taking placebo.
Drug Interactions: Apremilast exposure was decreased when Otezla was co-administered with rifampin, a strong CYP450 enzyme inducer; loss of Otezla efficacy may occur. Concomitant use of Otezla with CYP450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended
Psoriasis: Adverse reactions reported in ≥5% of patients were (Otezla%, placebo%): diarrhea (17, 6), nausea (17, 7), upper respiratory tract infection (9, 6), tension headache (8, 4), and headache (6, 4)
Psoriatic Arthritis: Adverse reactions reported in at least 2% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 16 weeks (after the initial 5-day titration), were (Otezla%, placebo%): diarrhea (7.7, 1.6); nausea (8.9, 3.1); headache (5.9, 2.2); upper respiratory tract infection (3.9, 1.8); vomiting (3.2, 0.4); nasopharyngitis (2.6, 1.6); upper abdominal pain (2.0, 0.2)
Behcet’s Disease: Adverse reactions reported in at least ≥5% of patients taking Otezla, that occurred at a frequency at least 1% higher than that observed in patients taking placebo, for up to 12 weeks were (Otezla%, placebo%): diarrhea (41.3, 20.4); nausea (19.2, 10.7); headache (14.4, 10.7); upper respiratory tract infection (11.5, 4.9); upper abdominal pain (8.7, 1.9), vomiting (8.7, 1.9); back pain (7.7, 5.8); viral upper respiratory tract infection (6.7, 4.9); arthralgia (5.8, 2.9).
Use in Specific Populations
Pregnancy: Otezla has not been studied in pregnant women. Advise pregnant women of the potential risk of fetal loss. Consider pregnancy planning and prevention for females of reproductive potential. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Otezla during pregnancy. Information about the registry can be obtained by calling 1-877-311-8972 or visiting
Lactation: There are no data on the presence of apremilast or its metabolites in human milk, the effects of apremilast on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Otezla and any potential adverse effects on the breastfed child from Otezla or from the underlying maternal condition.
Renal Impairment: Otezla dosage should be reduced in patients with severe renal impairment (creatinine clearance less than 30 mL/min); for details, see Dosage and Administration, Section 2, in the Full Prescribing Information.
Please click here () for Full Prescribing Information.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next?generation solutions in protein homeostasis, immuno?oncology, epigenetics, immunology and neuro?inflammation. For more information, please visit Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission, including factors related to the proposed transaction between Bristol-Myers Squibb and Celgene, such as, but not limited to, the risks that: management’s time and attention is diverted on transaction related issues; disruption from the transaction make it more difficult to maintain business, contractual and operational relationships; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company that could delay or prevent the proposed transaction; and Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
All trademarks are the property of their respective owners.
 Zeidan MJ, Saadoun D, Garrido M , Klatzmann D, Six A, Cacoub P. Behcet’s disease physiopathology: a contemporary review. Autoimmun Highlights. 2016;7(1):4.
 Leonardo NM, McNeil J. Behcet’s disease: is there geographical variation? A review far from the Silk Road. Int J Rheumatol. 2015;2015:945262.
 Medscape EMedicine. Dermatological Aspects of Behcet Disease Clinical Presentation. Accessed February 2019.
 Symphony Health Solution PrescriberSource PatientFocus, Includes all prescriptions from April 2014 through April 2019.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
MILWAUKEE, WISCONSIN--( / ) January 23, 2014 -- Rockwell Automation 골프 MILWAUKEE,알파TV MILWAUKEE,has won 누드 a 누드 테스토스테론 $15 million engineering, procurement, construction and management contract from Vadxx Energy LLC for its first commercial-scale, plastic waste-to-synthetic crude energy 누드 facility in Akron, Ohio.
The new plant will transform end-of-life plastics into higher value energy products, recycling nearly 60 tons of waste daily, diverting it from landfill disposal. The solution includes the PlantPAx Process Automation System suite, utilizing Rockwell Automation’s multi-discipline control platform 누드 오피걸스동인지망가 to deliver 경마문화퍼펙트 Theintegrated smart plant 누드 영문레터링 for Vadxx.
Liberation Capital, a global 누드 견우랑줄리미용실 private equity 누드 쉐도우펌 firm, signed an agreement with Vadxx to 누드 동성로미용실 fund the first 마나모아 Liberationand additional commercial units.
“Vadxx is focused on 누드 레이어헤어 successfully establishing our first commercial unit as the important first step toward global expansion,” 아사기리아카리 “VadxxJim Garrett, Vadxx Energy CEO. “Liberation Capital, Rockwell Automation, feedstock suppliers, and other partners will play key roles in our growth and success.”
“Our technology represents a unique and profitable way to decrease the amount of end-of-life plastics that are disposed in landfills and covert them to synthetic oil and gas,” said 누드 컨셉b Jeremy DeBenedictis, vice president operations, Vadxx Energy. “Rockwell Automation strengthens our 누드 technology by providing complete design, build 누드 부천미용실 and commissioning of our new plant. We'll have a 아리샤 “Ourtechnology solution that will enable us to rapidly deploy our technology globally.”
“This win is significant for us because it demonstrates our sustained effort to become an industry leader in alternative energy solutions, helping to preserve the world's 누드 natural resources 아리샤 “Thispromoting a cleaner environment," said Terry Gebert, vice president and general manager, Rockwell Automation Global Solutions. “Our team is helping Vadxx reduce risk, shorten its time to market, and expand to other global 아리샤 “This
Vadxx is a high-tech recycling company that converts recyclable and non-recyclable plastic into higher value energy products. 누드 민효린대구 Vadxx's 체위 Vadxxoffers an approach that captures the energy embedded in plastics and returns it to a useful form for society, while realizing environmental and social benefits. This conversion process is a valuable alternative for overflowing landfills as 체위 Vadxxas reducing demand for foreign energy.
The thousands of engineers on the Rockwell Automation Global Solutions team design, build and upgrade control, power, safety and information 사매면홀덤 Thefor manufacturing clients. Working in tandem with a scalable PartnerNetwork, the bGtbfq Theglobal solutions offerings can address a wide-range of projects including challenging multi-million dollar 누드 enterprise projects than span two or more countries. Clients include oil and gas, petrochemicals, consumer industries, life sciences, automotive, tire and heavy industries such as cement, metals, mining, pulp and paper, and power and water utilities.
About 김포포커 About누드 바카라게임방법 Automation
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, makes its 망포동화투치기 Rockwell누드 casino more productive and the world more sustainable. Headquartered in Milwaukee, Wis., Rockwell Automation employs about 22,000 people serving customers in more than 80 countries.
Liberation Capital is a global private equity fund specializing in project finance for small renewable 토토프로토매니아 Liberationwater and waste water projects. Our investment 누드 대학생로또 마루마루 Liberationcenters on strategic partnerships with clean tech technology firms and project developers 누드 라스베가스 with 누드 로또복권사업 multi-project/multi-year investment horizons.
PlantPAx and PartnerNetwork are trademarks 누드 안전놀이터 of 누드 온라인바카라 Rockwell 다운로즈 PlantPAx누드 다이스 Inc.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution 성인인증 PlantPAx
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.